World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
24343
World Ranking
13763
National Ranking
6982

Overview

Fredrick B. Hagemeister is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their primary field of research is Medicine, with significant contributions in subfields such as Pathology and Forensic Medicine, Oncology, Genetics, Neurology, and Immunology.

Their work focuses predominantly on topics including Lymphoma Diagnosis and Treatment, CAR-T cell therapy research, Chronic Lymphocytic Leukemia Research, Viral-associated cancers and disorders, CNS Lymphoma Diagnosis and Treatment, Immune Cell Function and Interaction, and Cancer Genomics and Diagnostics.

Notable recent publications by Fredrick B. Hagemeister include:

  • Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma (2020, Haematologica)
  • Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma (2020, Blood Advances)
  • Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression (2022, Blood Cancer Discovery)
  • Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma (2021, Journal of Clinical Oncology)
  • Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial (2022, The Lancet Oncology)

Frequent coauthors in Hagemeister's research include:

  • Jason R. Westin
  • Sattva S. Neelapu
  • Loretta J. Nastoupil
  • Christopher R. Flowers
  • Luis Fayad

Research published by Hagemeister has commonly appeared in established journals such as:

  • Blood
  • Journal of Clinical Oncology
  • Blood Advances
  • Leukemia & lymphoma/Leukemia and lymphoma
  • Clinical Cancer Research

Best Publications

  • Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).

    WS Velasquez;F Cabanillas;P Salvador;P McLaughlin

  • Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

    Deborah A. Thomas;Stefan Faderl;Susan O'Brien;Carlos Bueso-Ramos

  • Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

    Jason R Westin;Fuliang Chu;Min Zhang;Luis E Fayad

  • ESHAP--an Effective Chemotherapy Regimen in Refractory and Relapsing Lymphoma: A 4-year Follow-Up Study

    W. S. Velasquez;P. McLaughlin;Susan L Tucker;Fredrick B Hagemeister

  • Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality

    Issa F. Khouri;Rima M. Saliba;Sergio A. Giralt;Ming Sheng Lee

  • Double hit lymphoma: the MD Anderson Cancer Center clinical experience.

    Yasuhiro Oki;Mansoor Noorani;Pei Lin;Richard E. Davis

  • Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.

    I F Khouri;J Romaguera;H Kantarjian;J L Palmer

  • Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.

    Issa F Khouri;Peter McLaughlin;Rima M Saliba;Chitra Hosing

  • Risk Factors, Treatment, and Outcome of Central Nervous System Recurrence in Adults With Intermediate-Grade and Immunoblastic Lymphoma

    Koen van Besien;Chul S. Ha;Sandy Murphy;Peter McLaughlin

  • IMVP-16: An Effective Regimen for Patients With Lymphoma Who Have Relapsed After Initial Combination Chemotherapy

    Fernando Cabanillas;Fredrick B. Hagemeister;Gerald P. Bodey;Emil J. Freireich

  • Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma.

    Peter McLaughlin;Fredrick B. Hagemeister;Jorge E. Romaguera;Andreas H. Sarris

  • Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

    Michael Wang;Luis Fayad;Nicolaus A Wagner-Bartak;Liang Zhang

  • Results of MIME salvage regimen for recurrent or refractory lymphoma

    Fernando Cabanillas;Fredrick B. Hagemeister;Peter McLaughlin;William S. Velasquez

  • Chemotherapy induces transient sex chromosomal and autosomal aneuploidy in human sperm.

    Wendie A. Robbins;Marvin L. Meistrich;Dan Moore;Fredrick B. Hagemeister

  • Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

    Jorge E. Romaguera;Luis E. Fayad;Lei Feng;Kimberly Hartig

  • Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

    Nathan H Fowler;R Eric Davis;Seema Rawal;Loretta Nastoupil

  • Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma.

    John R. Redman;Fernando Cabanillas;William S. Velasquez;Peter McLaughlin

  • Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapy.

    M F da Cunha;M L Meistrich;L M Fuller;J H Cundiff

  • Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.

    S Jagannath;J O Armitage;K A Dicke;S L Tucker

  • Improvement of Overall and Failure-Free Survival in Stage IV Follicular Lymphoma: 25 Years of Treatment Experience at The University of Texas M.D. Anderson Cancer Center

    Qi Liu;Luis Fayad;Fernando Cabanillas;Fredrick B. Hagemeister

Frequent Co-Authors

Luis Fayad
Luis Fayad The University of Texas MD Anderson Cancer Center
Peter McLaughlin
Peter McLaughlin The University of Texas MD Anderson Cancer Center
Fernando Cabanillas
Fernando Cabanillas The University of Texas MD Anderson Cancer Center
Anas Younes
Anas Younes AstraZeneca (United Kingdom)
Larry W. Kwak
Larry W. Kwak City Of Hope National Medical Center
Issa F. Khouri
Issa F. Khouri The University of Texas MD Anderson Cancer Center
Andre Goy
Andre Goy Hackensack University Medical Center
L. Jeffrey Medeiros
L. Jeffrey Medeiros The University of Texas MD Anderson Cancer Center
Richard E. Champlin
Richard E. Champlin The University of Texas MD Anderson Cancer Center
Sergio Giralt
Sergio Giralt Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always follow a traditional path. The growing demand for healthcare professionals has opened doors to a variety of online degree programs, making it easier to enter the field from different backgrounds.

For those interested in patient care, there are nursing schools with high acceptance rates that provide accessible entry points, even for students with unconventional academic histories. Some aspiring nurses seek programs that are more flexible with their prerequisites. In such cases, looking into nursing school without teas test requirements can help you get started more quickly.

Not all medical careers require direct patient interaction. If you’re interested in the administrative side, consider healthcare administration programs that teach leadership, policy, and management skills. Alternatively, those looking for a fast entry into the medical field with the option of remote work may benefit from enrolling in accredited medical billing and coding schools with financial aid.

Whichever route you choose, these online options provide flexibility, a range of career opportunities, and support pathways for diverse learners.

Best Scientists Citing Fredrick B. Hagemeister

Trending Scientists